Tirzepatide
Dual incretin receptor agonist with larger weight reduction than semaglutide in head-to-head trials.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: Mounjaro · Zepbound
Dual incretin receptor agonist with larger weight reduction than semaglutide in head-to-head trials.
Evidence Intelligence Score™
- Preclinical
- Pilot human
- RCT← current
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data8.8
- Safety maturityFollow-up depth and adverse-event signal6.5
- Mechanism confidencePathway specificity and clarity6.7
- Clinical readinessDistance to physician-prescribable use7.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts4.4
- Long-term dataFollow-up beyond initial trial windows5.4
- Translational confidenceAnimal → human signal preservation7.8
Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.
Effect sizes outside trial populations and durations beyond the studied window remain less characterized.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: maturing. Expect the consensus to harden as multi-site replications publish.
Weight / fat reduction
2 studies- strongMalhotra A, Grunstein RR, Fietze I, et al.
AHI -25 events/hr and ~18% weight loss vs placebo at 52 weeks.
RCTn=4692024unreviewed - strongJastreboff AM, Aronne LJ, Ahmad NN, et al.
-20.9% with tirzepatide 15 mg/wk vs -3.1% placebo at 72 weeks.
RCTn=2,5392022unreviewed
Cardiometabolic health
2 studies- strongDahl D, Onishi Y, Norwood P, et al.
HbA1c -2.1 to -2.4%; weight -5.4 to -8.8 kg vs placebo at 40 wk.
RCTn=4752022unreviewed - strongFrias JP, Davies MJ, Rosenstock J, et al.
Tirzepatide HbA1c -up to 2.3 pp; weight -12.4 kg at 40 wk, superior to sema 1 mg.
RCTn=1,8792021unreviewed
Appetite & food-noise suppression
1 study- moderateHeise T, DeVries JH, Urva S, et al.
Tirzepatide significantly reduced energy intake and increased satiety vs sema and placebo over 28d in T2D.
RCTn=1172023unreviewed
Weight / fat reduction
2 regimensCardiometabolic health
1 regimenNausea, diarrhea, vomiting; hypoglycemia rare without insulin/SU.
40-wk trial in T2D on metformin.
Appetite & food-noise suppression
1 regimenMild-moderate GI AEs during escalation.
T2D participants; ad-libitum lunch + appetite VAS at steady state.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
8 brands across three tiers.
Medicine
2 brandsRegulator-approved finished medicines. Prescribed for specific indications, manufactured under GMP, distributed through licensed pharmacies.
Compounded (US 503A)
3 brandsPatient-specific preparations from US 503A compounding pharmacies. Require a valid prescription, not FDA-approved as finished drugs. Check the pharmacy's licence and the active ingredient's status on the FDA 503A bulks list.
Research-use only
3 brandsSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.